{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T23:30:18Z","timestamp":1712791818852},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s11899-008-0006-x","type":"journal-article","created":{"date-parts":[[2008,1,30]],"date-time":"2008-01-30T14:14:04Z","timestamp":1201702444000},"page":"31-36","source":"Crossref","is-referenced-by-count":5,"title":["Diagnosis and management of chronic myelomonocytic leukemia"],"prefix":"10.1007","volume":"3","author":[{"given":"Francesco","family":"Onida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miloslav","family":"Beran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"6_CR1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"J.M. Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189\u2013199.","journal-title":"Br J Haematol"},{"key":"6_CR2","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"J.W. Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD, et al.: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292\u20132302.","journal-title":"Blood"},{"key":"6_CR3","first-page":"218","volume":"3","author":"F. Onida","year":"2004","unstructured":"Onida F, Beran M: Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 2004, 3:218\u2013226.","journal-title":"Curr Hematol Rep"},{"key":"6_CR4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","volume":"87","author":"J.M. Bennett","year":"1994","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al.: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994, 87:746\u2013754.","journal-title":"Br J Haematol"},{"key":"6_CR5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P. Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, Le Beau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079\u20132088.","journal-title":"Blood"},{"key":"6_CR6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0145-2126(00)00159-4","volume":"25","author":"J. Voglov\u00e1","year":"2001","unstructured":"Voglov\u00e1 J, Chrob\u00e1k L, Neuwirtov\u00e1 R, et al.: Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia-distinct subgroups or two stages of the same disease? Leuk Res 2001, 25:493\u2013499.","journal-title":"Leuk Res"},{"issue":"Suppl1","key":"6_CR7","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0145-2126(97)81242-8","volume":"21","author":"T. Vallesp\u00ed","year":"1997","unstructured":"Vallesp\u00ed T, Blanco A, S\u00e1nchez-Morata C, et al.: Proliferative chronic myelomonocytic leukemia (P-CMML) emerging after splenectomy in two patients with dysplastic CMML (D-CMML) [abstract]. Leuk Res 1997; 21(Suppl 1):S8.","journal-title":"Leuk Res"},{"issue":"Suppl1","key":"6_CR8","first-page":"2607","volume":"98","author":"F. Onida","year":"2001","unstructured":"Onida F, Kantarjian H, Ball G, et al.: The dysplastic versus proliferative classification dilemma of chronic myelomonocytic leukemia: a retrospective single institution analysis of 273 patients [abstract]. Blood 2001, 98(Suppl 1):2607. Abstract 622a.","journal-title":"Blood"},{"key":"6_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","volume":"68","author":"A. Worsley","year":"1988","unstructured":"Worsley A, Oscier DG, Stevens J, et al.: Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988, 68:17\u201321.","journal-title":"Br J Haematol"},{"key":"6_CR10","first-page":"52","volume":"6","author":"C. Aul","year":"1992","unstructured":"Aul C, Gattermann N, Heyll A, et al.: Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992, 6:52\u201359.","journal-title":"Leukemia"},{"key":"6_CR11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F. Onida","year":"2002","unstructured":"Onida F, Kantarjian HM, Smith TL, et al.: Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002, 99:840\u2013849.","journal-title":"Blood"},{"key":"6_CR12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2002-01-0330","volume":"100","author":"U. Germing","year":"2002","unstructured":"Germing U, Strupp C, Aivado M, et al.: New prognostic parameters for chronic myelomonocytic leukemia. Blood 2002, 100:731\u2013732.","journal-title":"Blood"},{"key":"6_CR13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","volume":"45","author":"U. Germing","year":"2004","unstructured":"Germing U, Kundgen A, Gattermann N: Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004, 45:1311\u20131318.","journal-title":"Leuk Lymphoma"},{"key":"6_CR14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1080\/10428190701216386","volume":"48","author":"M. Beran","year":"2007","unstructured":"Beran M, Wen S, Shen Y, et al.: Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007, 48:1150\u20131160.","journal-title":"Leuk Lymphoma"},{"key":"6_CR15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","volume":"77","author":"T.R. Golub","year":"1994","unstructured":"Golub TR, Barker GF, Lovett M, et al.: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307\u2013316.","journal-title":"Cell"},{"key":"6_CR16","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1182\/blood.V91.12.4419","volume":"91","author":"T.S. Ross","year":"1998","unstructured":"Ross TS, Bernard OA, Berger R, et al.: Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998, 91:4419\u20134426.","journal-title":"Blood"},{"key":"6_CR17","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood.V97.12.3910","volume":"97","author":"J. Schwaller","year":"2001","unstructured":"Schwaller J, Anastasiadou E, Cain D, et al.: H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 2001, 97:3910\u20133918.","journal-title":"Blood"},{"key":"6_CR18","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1182\/blood.V98.8.2518","volume":"98","author":"M.K. Magnusson","year":"2001","unstructured":"Magnusson MK, Meade KE, Brown KE, et al.: Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001, 98:2518\u20132525.","journal-title":"Blood"},{"key":"6_CR19","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J. Jelinek","year":"2005","unstructured":"Jelinek J, Oki Y, Gharibyan V, et al.: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in LMMC, Philadelphia chromosome-negative LMC, and megakaryocytic leukemia. Blood 2005, 106:3370\u20133373.","journal-title":"Blood"},{"key":"6_CR20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"R.L. Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, et al.: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673\u2013683.","journal-title":"Nat Rev Cancer"},{"key":"6_CR21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1445-5994.2001.00074.x","volume":"31","author":"I. Kerridge","year":"2001","unstructured":"Kerridge I, Spencer A, Azzi A, et al.: Response to erythropoietin in chronic myelomonocytic leukaemia. Intern Med J 2001, 31:371\u2013372.","journal-title":"Intern Med J"},{"key":"6_CR22","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.22343","volume":"107","author":"P. Giraldo","year":"2006","unstructured":"Giraldo P, Nomdedeu B, Loscertales J, et al.: Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006, 107:2807\u20132816.","journal-title":"Cancer"},{"key":"6_CR23","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1200\/JCO.2005.04.1012","volume":"23","author":"M. Arshad","year":"2005","unstructured":"Arshad M, Seiter K, Bilaniuk J, et al.: Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005, 23:8533\u20138534.","journal-title":"J Clin Oncol"},{"key":"6_CR24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","volume":"347","author":"J.F. Apperley","year":"2002","unstructured":"Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481\u2013487.","journal-title":"N Engl J Med"},{"key":"6_CR25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00277-006-0247-5","volume":"86","author":"M. Drechsler","year":"2007","unstructured":"Drechsler M, Hildebrandt B, K\u00fcndgen A, et al.: Fusion of H4\/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol 2007, 86:353\u2013354.","journal-title":"Ann Hematol"},{"key":"6_CR26","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","volume":"88","author":"E. Wattel","year":"1996","unstructured":"Wattel E, Guerci A, Hecquet B, et al.: A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996, 88:2480\u20132487.","journal-title":"Blood"},{"key":"6_CR27","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473","volume":"88","author":"M. Beran","year":"1996","unstructured":"Beran M, Kantarjian H, O\u2019Brien S, et al.: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996, 88:2473\u20132479.","journal-title":"Blood"},{"key":"6_CR28","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/cncr.22186","volume":"107","author":"A. Quintas-Cardama","year":"2006","unstructured":"Quintas-Cardama A, Kantarjian H, O\u2019Brien S, et al.: Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 2006, 107:1525\u20131529.","journal-title":"Cancer"},{"key":"6_CR29","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/10428190701332449","volume":"48","author":"C. Strupp","year":"2007","unstructured":"Strupp C, Knipp S, Hartmann J, et al.: A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma 2007, 48:1161\u20131166.","journal-title":"Leuk Lymphoma"},{"key":"6_CR30","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/sj.leu.2404811","volume":"21","author":"U. Platzbecker","year":"2007","unstructured":"Platzbecker U, Mohr B, von Bonin M, et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 2007, 21:2384\u20132385.","journal-title":"Leukemia"},{"key":"6_CR31","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","volume":"17","author":"M. Beran","year":"1999","unstructured":"Beran M, Estey E, O\u2019Brien S, et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999, 17:2819\u20132830.","journal-title":"J Clin Oncol"},{"key":"6_CR32","first-page":"624a","volume":"98","author":"M. Beran","year":"2001","unstructured":"Beran M, Onida M, Cortes J, et al.: Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia [abstract]. Blood 2001, 98:624a.","journal-title":"Blood"},{"key":"6_CR33","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"L.R. Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429\u20132440.","journal-title":"J Clin Oncol"},{"key":"6_CR34","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","volume":"11","author":"E. Kaminskas","year":"2005","unstructured":"Kaminskas E, Farrell A, Abraham S, et al.: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005, 11:3604\u20133608.","journal-title":"Clin Cancer Res"},{"key":"6_CR35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","volume":"18","author":"P. Wijermans","year":"2000","unstructured":"Wijermans P, Lubbert M, Verhoef G, et al.: Low-dose 5-aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000, 18:956\u2013962.","journal-title":"J Clin Oncol"},{"key":"6_CR36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","volume":"109","author":"H. Kantarjian","year":"2007","unstructured":"Kantarjian H, Oki Y, Garcia-Manero G, et al.: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52\u201357.","journal-title":"Blood"},{"key":"6_CR37","first-page":"623a","volume":"98","author":"R. Kurzrock","year":"2001","unstructured":"Kurzrock R, Sebti SM, Kantarjian HM, et al.: Phase I study of a farnesyltransferase inhibitor, R115777, in patients with myelodysplastic syndrome [abstract]. Blood 2001, 98:623a.","journal-title":"Blood"},{"key":"6_CR38","doi-asserted-by":"crossref","first-page":"68a","DOI":"10.1182\/blood.V104.11.68.68","volume":"104","author":"R. Kurzrock","year":"2004","unstructured":"Kurzrock R, Fenaux P, Raza A, et al.: High risk myelodysplastic syndrome (MDS): first result of international phase 2 study with oral farnesyl transferase inhibitor R22577 (Zarnestra\u2122) [abstract]. Blood 2004, 104:68a.","journal-title":"Blood"},{"key":"6_CR39","doi-asserted-by":"crossref","first-page":"421a","DOI":"10.1182\/blood-2002-12-3834","volume":"102","author":"E. Feldman","year":"2003","unstructured":"Feldman E, Cortes J, Holyoake T, et al.: Continuous oral Lonafarnib (SarasarTM) for the treatment of patients with myelodysplastic syndrome [abstract]. Blood 2003, 102:421a.","journal-title":"Blood"},{"key":"6_CR40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbmt.2005.05.008","volume":"11","author":"D.M. Kerbauy","year":"2005","unstructured":"Kerbauy DM, Chyou F, Gooley T, et al.: Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005, 11:713\u2013720.","journal-title":"Biol Blood Marrow Transplant"},{"key":"6_CR41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","volume":"118","author":"N. Kroger","year":"2002","unstructured":"Kroger N, Zabelina T, Guardiola P, et al.: Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002, 118:67\u201373.","journal-title":"Br J Haematol"},{"key":"6_CR42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","volume":"37","author":"M.A. Elliott","year":"2006","unstructured":"Elliott MA, Tefferi A, Hogan WJ, et al.: Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006, 37:1003\u20131008.","journal-title":"Bone Marrow Transplant"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-008-0006-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0006-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T09:12:24Z","timestamp":1588324344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-008-0006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s11899-008-0006-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}